New drug to stop 'Ozempic butt' muscle loss side effect of obesity jabs
A new drug called apitegromab is being studied for its potential to prevent muscle loss in patients using GLP-1 obesity medications like Ozempic and Wegovy. Clinical trials suggest the drug helps maintain muscle mass while fat is lost, addressing concerns about 'Ozempic butt'.
Why it matters
As obesity drugs become widespread, managing side effects like muscle atrophy is critical for long-term patient health and safety.
Share Save Add as preferred on Google Michelle Roberts Digital health editor Getty Images A new drug called apitegromab could help people on obesity jabs avoid unwanted muscle decline that s been linked to flat bums or "Ozempic butt", according to research in Nature Medicine journal.
The report relies on medical research findings and provides a balanced view of the drug's current experimental status.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in